Database Query Results : Cisplatin, ,

Cisplatin, Cisplatin: Click to Expand ⟱

Features:

Cisplatin is a chemotherapy medication used to treat various types of cancer. It is a platinum-based drug that works by interfering with the DNA of cancer cells, preventing them from reproducing and ultimately leading to cell death.
Cisplatin (cis-diamminedichloroplatinum II; CDDP) is a platinum-based chemotherapeutic agent that forms covalent DNA crosslinks, primarily intrastrand adducts at adjacent guanine bases. These distort DNA structure, block replication and transcription, and activate DNA damage response pathways (ATM/ATR → p53), leading to cell-cycle arrest and apoptosis. Secondary mechanisms include ROS generation, stress MAPK activation, and modulation of NF-κB. Clinical resistance frequently involves enhanced DNA repair (ERCC1/NER), altered drug transport (CTR1, ATP7A/B), and increased antioxidant defenses. Major toxicities include nephrotoxicity, ototoxicity, and peripheral neuropathy.

Rank	Pathway / Axis	Cancer / Tumor Context	Normal Tissue Context	TSF	Primary Effect	Notes / Interpretation
1	DNA crosslink formation (intrastrand adducts)	DNA adducts ↑; replication block ↑	Normal dividing cells also affected	P, R, G	Direct DNA cytotoxicity	Cisplatin forms covalent intrastrand crosslinks (primarily at adjacent guanines), distorting DNA and blocking replication and transcription.
2	DNA damage response (ATM / ATR → p53)	Checkpoint activation ↑; p53 signaling ↑	↔ (toxicity in proliferating tissues)	R, G	Damage signaling cascade	DNA distortion activates ATM/ATR pathways leading to p53-mediated cell-cycle arrest and apoptosis.
3	Intrinsic apoptosis (mitochondrial pathway)	Bax ↑; Bcl-2 ↓; caspase-9/3 ↑	Nephrotoxicity & ototoxicity risk	G	Execution of cell death	Persistent DNA damage triggers mitochondrial outer membrane permeabilization and caspase activation.
4	Cell-cycle arrest (G2/M emphasis)	G2/M arrest ↑	↔	G	Cytostasis → apoptosis	Cells accumulate in G2/M phase due to unrepaired DNA lesions.
5	ROS generation / oxidative stress	ROS ↑ (secondary mechanism)	Oxidative injury ↑ (kidney, cochlea)	R, G	Stress amplification	Cisplatin increases mitochondrial ROS and oxidative stress, contributing to cytotoxicity and organ toxicity.
6	MAPK signaling (JNK / p38 activation)	Stress MAPK activation ↑	↔	R, G	Stress-response signaling	JNK and p38 activation contribute to apoptosis and stress signaling.
7	NF-κB activation (resistance axis)	NF-κB ↑ may promote survival	↔	R, G	Resistance modulation	NF-κB activation can reduce sensitivity; inhibition enhances cytotoxicity in some models.
8	DNA repair pathways (NER / ERCC1)	NER ↑ → resistance	—	G	Resistance determinant	Nucleotide excision repair (ERCC1) removes platinum adducts; high ERCC1 correlates with resistance.
9	Drug transport (CTR1 uptake; ATP7A/B efflux)	CTR1 ↓ or ATP7A/B ↑ → resistance	—	G	Exposure constraint	Copper transporters influence intracellular cisplatin accumulation and resistance.
10	Clinical toxicity profile	—	Nephrotoxicity, ototoxicity, neurotoxicity	—	Translation constraint	Major dose-limiting toxicities arise from DNA damage and oxidative stress in normal tissues.

Time-Scale Flag (TSF): P / R / G

P: 0–30 min (DNA aquation and initial adduct formation)
R: 30 min–3 hr (checkpoint activation / stress signaling)
G: >3 hr (apoptosis, phenotype outcomes, resistance development)

Scientific Papers found: Click to Expand⟱

1339-

2DG,

Cisplatin,

2-Deoxy-d-Glucose Combined with Cisplatin Enhances Cytotoxicity via Metabolic Oxidative Stress in Human Head and Neck Cancer Cells

in-vitro,

HNSCC,

FaDu

"highlight2" >ChemoSen↑, "highlight2" >ROS↑, "highlight2" >GSH↓, "highlight2" >other↓,

1295-

AG,

Cisplatin,

Chemosensitizing Effect of Astragalus Polysaccharides on Nasopharyngeal Carcinoma Cells by Inducing Apoptosis and Modulating Expression of Bax/Bcl-2 Ratio and Caspases

in-vivo,

Laryn,

mice

"highlight2" >AntiTum↑, "highlight2" >Apoptosis↑, "highlight2" >Bcl-2↓, "highlight2" >BAX↑, "highlight2" >Casp3↑, "highlight2" >Casp9↑, "highlight2" >Bax:Bcl2↑,

322-

AgNPs,

Cisplatin,

Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin

in-vitro,

Ovarian,

A2780S

 25nm AgNPs capped with polyvinylpyrrolidone (PVP

 15ug/mL

 IC50: 7.9ug/mL : 3.1uM for combination treatment

in-vitro,

Ovarian,

SKOV3

in-vitro,

Ovarian,

OVCAR-3

 745ug/mL

 less sensitive to AgNPs

"highlight2" >ROS↑, "highlight2" >DNAdam↑, "highlight2" >GSH/GSSG↓,

257-

AL,

Cisplatin,

Allicin Overcomes Hypoxia Mediated Cisplatin Resistance in Lung Cancer Cells through ROS Mediated Cell Death Pathway and by Suppressing Hypoxia Inducible Factors

in-vitro,

NSCLC,

A549

 10μg/ml (LD) and 40μg/ml (HD) allicin for 24hr

 ~30µg/ml

"highlight2" >ROS↑, "highlight2" >HIF-1↓, "highlight2" >E-cadherin↑, "highlight2" >N-cadherin↓, "highlight2" >antiOx↓, "highlight2" >Dose↝,

299-

ALA,

Cisplatin,

PacT,

Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line

in-vitro,

Ovarian,

OVCAR-3

"highlight2" >MMP9↓, "highlight2" >MMP11↓, "highlight2" >MAPK↓,

1235-

ALA,

Cisplatin,

α-Lipoic acid prevents against cisplatin cytotoxicity via activation of the NRF2/HO-1 antioxidant pathway

in-vitro,

Nor,

HEI-OC1

20μM cisplatin, 0-2mM(ALA)

ex-vivo,

NA,

"highlight2" >ROS↑, "highlight2" >HO-1↓, "highlight2" >*toxicity↓, "highlight2" >chemoP↑, "highlight2" >*ROS↓, "highlight2" >*HO-1↑, "highlight2" >*SOD1↑, "highlight2" >*NRF2↑,

1350-

And,

Cisplatin,

Synergistic antitumor effect of Andrographolide and cisplatin through ROS-mediated ER stress and STAT3 inhibition in colon cancer

in-vitro,

Colon,

"highlight2" >ChemoSen↑, "highlight2" >ER Stress↑, "highlight2" >STAT3↓, "highlight2" >ROS↑,

578-

Api,

Cisplatin,

Apigenin enhances the cisplatin cytotoxic effect through p53-modulated apoptosis

in-vitro,

Lung,

A549

30 uM

Multiple tumor cell types

in-vitro,

BC,

MCF-7

apigenin at 30 µM with cisplatin at 2.5, 5.0, and 10.0 µM

in-vitro,

CRC,

HCT116

in-vitro,

Pca,

HeLa

in-vitro,

Lung,

H1299

"highlight2" >p‑P53↑,

581-

Api,

Cisplatin,

The natural flavonoid apigenin sensitizes human CD44+ prostate cancer stem cells to cisplatin therapy

in-vitro,

Pca,

CD44+

15uM / 7.5uM for 48

CD44+PCa

"highlight2" >Bcl-2↓, "highlight2" >survivin↓, "highlight2" >Casp8↑, "highlight2" >P53↑, "highlight2" >Sharpin↓, "highlight2" >APAF1↑, "highlight2" >p‑Akt↓, "highlight2" >NF-kB↓, "highlight2" >P21↑, "highlight2" >Cyc↓, "highlight2" >CDK2↓, "highlight2" >CDK4/6↓, "highlight2" >Snail↓, "highlight2" >ChemoSen↑,

583-

Api,

Cisplatin,

Apigenin suppresses GLUT-1 and p-AKT expression to enhance the chemosensitivity to cisplatin of laryngeal carcinoma Hep-2 cells: an in vitro study

in-vitro,

Laryn,

HEp2

40uM - 160 uM

"highlight2" >PI3K/Akt↓, "highlight2" >GLUT1↓, "highlight2" >Akt↓,

584-

Api,

Cisplatin,

Apigenin potentiates the antitumor activity of 5-FU on solid Ehrlich carcinoma: Crosstalk between apoptotic and JNK-mediated autophagic cell death platforms

in-vivo,

Var,

Eighty Swiss albino male mice

"highlight2" >Beclin-1↑, "highlight2" >Casp3↑, "highlight2" >Casp9↑, "highlight2" >JNK↑, "highlight2" >Mcl-1↓, "highlight2" >Ki-67↓,

564-

ART/DHA,

Cisplatin,

Dihydroartemisinin as a Putative STAT3 Inhibitor, Suppresses the Growth of Head and Neck Squamous Cell Carcinoma by Targeting Jak2/STAT3 Signaling

in-vitro,

NA,

HN30

"highlight2" >JAK2↓, "highlight2" >STAT3↓, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >Mcl-1↓, "highlight2" >Bcl-xL↓, "highlight2" >cycD1/CCND1↓, "highlight2" >VEGF↓, "highlight2" >TumCCA↑, "highlight2" >ChemoSen↑,

1368-

Ash,

Cisplatin,

Withania somnifera Root Extract Enhances Chemotherapy through ‘Priming’

in-vitro,

Colon,

HT-29

1 μg/mL, 5 μg/mL and 10 μg/mL W. somnifera for 48 h

in-vitro,

BC,

MDA-MB-231

"highlight2" >tumCV↓, "highlight2" >*toxicity↓, "highlight2" >ROS↑, "highlight2" >mitResp↓, "highlight2" >ChemoSen↑,

5426-

ASTX,

Cisplatin,

Astaxanthin Prevents a Decrease of Hemopoietic Activity in Head and Neck Cancer Patients Receiving Cisplatin Chemotherapy (Randomized Controlled Trial)

Trial,

HNSCC,

astaxanthin 2x4 mg

"highlight2" >ROS↓, "highlight2" >SOD↑, "highlight2" >MDA↓, "highlight2" >eff↑,

2628-

Ba,

Cisplatin,

Baicalein alleviates cisplatin-induced acute kidney injury by inhibiting ALOX12-dependent ferroptosis

in-vitro,

Nor,

HK-2

"highlight2" >*RenoP↑, "highlight2" >*12LOX↓, "highlight2" >*Ferroptosis↓,

2627-

Ba,

Cisplatin,

Baicalein, a Bioflavonoid, Prevents Cisplatin-Induced Acute Kidney Injury by Up-Regulating Antioxidant Defenses and Down-Regulating the MAPKs and NF-κB Pathways

"highlight2" >RenoP↑, "highlight2" >*iNOS↑, "highlight2" >*TNF-α↓, "highlight2" >*IL6↓, "highlight2" >*NF-kB↓, "highlight2" >*MAPK↓, "highlight2" >*ERK↓, "highlight2" >*JNK↓, "highlight2" >*antiOx↑, "highlight2" >*NRF2↓, "highlight2" >*HO-1↑, "highlight2" >*Cyt‑c∅, "highlight2" >*Casp3∅, "highlight2" >*Casp9∅, "highlight2" >*PARP∅,

2622-

Ba,

Cisplatin,

Rad,

Natural Baicalein-Rich Fraction as Radiosensitizer in Combination with Bismuth Oxide Nanoparticles and Cisplatin for Clinical Radiotherapy

in-vitro,

BC,

MDA-MB-231

in-vitro,

BC,

MCF-7

"highlight2" >RadioS↑,

5181-

BBR,

Cisplatin,

Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer

in-vitro,

GC,

SGC-7901

in-vitro,

GC,

BGC-823

"highlight2" >tumCV↓, "highlight2" >MDR1↓, "highlight2" >ChemoSen↑, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >mTOR↓,

730-

Bor,

Cisplatin,

The Effect of Boric Acid and Borax on Oxidative Stress, Inflammation, ER Stress and Apoptosis in Cisplatin Toxication and Nephrotoxicity Developing as a Result of Toxication

in-vivo,

NA,

rats

"highlight2" >*ROS↓, "highlight2" >*Inflam↓, "highlight2" >RenoP↑,

1450-

Bos,

Cisplatin,

3-Acetyl-11-keto-β-boswellic acid (AKBA) induced antiproliferative effect by suppressing Notch signaling pathway and synergistic interaction with cisplatin against prostate cancer cells

in-vitro,

Pca,

DU145

16.50 µM at 48 h

"highlight2" >ROS↑, "highlight2" >MMP↓, "highlight2" >Casp↑, "highlight2" >Apoptosis↑, "highlight2" >Bax:Bcl2↑, "highlight2" >TumCCA?, "highlight2" >cycD1/CCND1↓, "highlight2" >CDK4↓, "highlight2" >P21↑, "highlight2" >p27↑, "highlight2" >NOTCH↓, "highlight2" >ChemoSen↑,

444-

CUR,

Cisplatin,

LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin on cisplatin resistance in the colorectal cancer cells

vitro+vivo,

CRC,

HCT8

10 μM, 48 h; 1 g/kg/week, 42 days

"highlight2" >TumVol↓, "highlight2" >Apoptosis↑, "highlight2" >Bcl-2↓, "highlight2" >Cyt‑c↑, "highlight2" >BAX↑, "highlight2" >cl‑Casp3↑, "highlight2" >cl‑PARP1↑, "highlight2" >miR-497↑, "highlight2" >KCNQ1OT1↓,

1411-

CUR,

Cisplatin,

Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects

Review,

Var,

"highlight2" >ChemoSen↑, "highlight2" >*ROS↓, "highlight2" >*NF-kB↓, "highlight2" >TumCCA↑,

949-

FIS,

ATAGJ,

Cisplatin,

Ai-Tong-An-Gao-Ji and Fisetin Inhibit Tumor Cell Growth in Rat CIBP Models by Inhibiting the AKT/HIF-1α Signaling Pathway

in-vivo,

BC,

Walker256

10,20,30g/day

in-vitro,

BC,

Walker256

10,20,30uM and 5uM(Cis)

indicating that the cisplatin group could substantially inhibit the migration of Walker 256 cells in both low and high dose fisetin groups

"highlight2" >Akt↓, "highlight2" >Hif1a↓, "highlight2" >p‑Akt↓,

1966-

GamB,

Cisplatin,

Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling

in-vitro,

Lung,

A549

in-vitro,

Lung,

NCIH1299

"highlight2" >TumCCA↑, "highlight2" >PARP↑, "highlight2" >eff↑, "highlight2" >ROS↑, "highlight2" >ChemoSen↑,

828-

GAR,

Cisplatin,

Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells

in-vitro,

Ovarian,

OVCAR-3

"highlight2" >tumCV↓, "highlight2" >cl‑PARP↑, "highlight2" >cl‑Casp3↑, "highlight2" >BAX↑, "highlight2" >p‑PI3K↓, "highlight2" >p‑Akt↓, "highlight2" >NF-kB↓,

805-

GAR,

Cisplatin,

PacT,

Garcinol Exhibits Anti-Neoplastic Effects by Targeting Diverse Oncogenic Factors in Tumor Cells

Review,

NA,

"highlight2" >ERK↓, "highlight2" >PI3K/Akt↓, "highlight2" >Wnt/(β-catenin)↓, "highlight2" >STAT3↓, "highlight2" >NF-kB↓, "highlight2" >ChemoSen↑, "highlight2" >COX2↓, "highlight2" >Casp3↑, "highlight2" >Casp9↑, "highlight2" >BAX↑, "highlight2" >Bcl-2↓, "highlight2" >VEGF↓, "highlight2" >TGF-β↓, "highlight2" >HATs↓, "highlight2" >E-cadherin↑, "highlight2" >Vim↓, "highlight2" >Zeb1↓, "highlight2" >ZEB2↓, "highlight2" >Let-7↑, "highlight2" >MMP9↓, "highlight2" >TumCCA↑, "highlight2" >ROS↑, "highlight2" >MMP↓, "highlight2" >IL6↓, "highlight2" >NOTCH1↓,

801-

GAR,

Cisplatin,

Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers

in-vivo,

HNSCC,

0.5 mg/kg

mouse

"highlight2" >Apoptosis↑, "highlight2" >cycD1/CCND1↓, "highlight2" >Bcl-2↓, "highlight2" >survivin↓, "highlight2" >VEGF↓, "highlight2" >TumCG↓, "highlight2" >Ki-67↓, "highlight2" >CD31↓,

1064-

LT,

Cisplatin,

Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells

vitro+vivo,

Lung,

LNM35

25-200μM

intraperitoneal injection (20mg/kg/day for 18days)

in-vitro,

CRC,

HT-29

in-vitro,

Liver,

HepG2

in-vitro,

BC,

MCF-7

in-vitro,

BC,

MDA-MB-231

"highlight2" >Casp3↑, "highlight2" >Casp7↑, "highlight2" >HDAC↓,

4781-

Lyco,

5-FU,

Chemo,

Cisplatin,

Antioxidant and anti-inflammatory activities of lycopene against 5-fluorouracil-induced cytotoxicity in Caco2 cells

in-vitro,

Colon,

Caco-2

"highlight2" >chemoP↑, "highlight2" >Inflam↓, "highlight2" >COX2↓, "highlight2" >IL1β↓, "highlight2" >IL6↓, "highlight2" >TNF-α↓, "highlight2" >ROS↑, "highlight2" >ChemoSen↑, "highlight2" >SOD↓,

4532-

MAG,

Cisplatin,

Magnolol Attenuates Cisplatin-Induced Muscle Wasting by M2c Macrophage Activation

in-vivo,

Var,

cisplatin-treated mice

"highlight2" >cachexia↓, "highlight2" >*IGF-1↑, "highlight2" >chemoP↑, "highlight2" >*M2 MC↑,

4518-

MAG,

Cisplatin,

Evaluating the Magnolol Anticancer Potential in MKN-45 Gastric Cancer Cells

in-vitro,

GC,

MKN45

"highlight2" >ChemoSen↑, "highlight2" >tumCV↓, "highlight2" >BAX↑, "highlight2" >Bcl-2↓, "highlight2" >P21↑, "highlight2" >P53↑, "highlight2" >MMP9↓,

2043-

PB,

Cisplatin,

Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin

in-vitro,

HNSCC,

UM-SCC-1

2 mM phenylbutyrate for 5 days

"highlight2" >ChemoSen↑, "highlight2" >eff↑, "highlight2" >HDAC↓, "highlight2" >BRCA1↓, "highlight2" >RadioS↑,

4920-

PEITC,

Cisplatin,

PEITC restores chemosensitivity in cisplatin-resistant non-small cell lung cancer by targeting c-Myc/miR-424-5p

vitro+vivo,

NSCLC,

A549

0, 0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64 μM

 mouse xenograft model

"highlight2" >TumCG↓, "highlight2" >ChemoSen↑, "highlight2" >cMyc↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >mTOR↓, "highlight2" >BioAv↝, "highlight2" >tumCV↓, "highlight2" >ChemoSen↑,

5183-

PEITC,

Cisplatin,

Phenethyl Isothiocyanate Induces Apoptosis Through ROS Generation and Caspase-3 Activation in Cervical Cancer Cells

in-vitro,

Cerv,

HeLa

in-vitro,

Nor,

HaCaT

"highlight2" >DNAdam↑, "highlight2" >Apoptosis↑, "highlight2" >ChemoSen↑, "highlight2" >ROS↑, "highlight2" >mt-ROS↑, "highlight2" >Casp↑, "highlight2" >Casp3↑, "highlight2" >selectivity↑, "highlight2" >TumCP↓, "highlight2" >tumCV↓, "highlight2" >eff↓,

4965-

PSO,

Cisplatin,

The synergistic antitumor effects of psoralidin and cisplatin in gastric cancer by inducing ACSL4-mediated ferroptosis

vitro+vivo,

GC,

HGC27

2.5 to 120 µM)

Xenograft experiments in nude mice

vitro+vivo,

GC,

MKN45

"highlight2" >TumCP↓, "highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >TumCG↓, "highlight2" >*toxicity↓, "highlight2" >eff↑, "highlight2" >Ferroptosis↑, "highlight2" >ACSL4↑, "highlight2" >GPx4↓, "highlight2" >ChemoSen↑, "highlight2" >chemoP↑, "highlight2" >AntiTum↑, "highlight2" >Sepsis↓,

4704-

PTS,

Cisplatin,

Pterostilbene Sensitizes Cisplatin-Resistant Human Bladder Cancer Cells with Oncogenic HRAS

in-vitro,

Bladder,

"highlight2" >PI3K↓, "highlight2" >mTOR↓, "highlight2" >P70S6K↓, "highlight2" >MEK↑, "highlight2" >ERK↑, "highlight2" >ChemoSen↑, "highlight2" >TumAuto↑,

5041-

SAS,

Cisplatin,

Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism

in-vitro,

CRC,

"highlight2" >xCT↓, "highlight2" >Inflam↓, "highlight2" >Apoptosis↓, "highlight2" >GSH↓, "highlight2" >ROS↑, "highlight2" >TumCG↓, "highlight2" >selectivity↑, "highlight2" >eff↑, "highlight2" >eff↓,

2184-

SK,

Cisplatin,

PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis

in-vitro,

CRC,

T24/HTB-9

"highlight2" >PKM2↓, "highlight2" >ChemoSen↑, "highlight2" >Necroptosis↑,

2182-

SK,

Cisplatin,

Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway

in-vitro,

Lung,

A549

2 µM, 4 µM, 6 µM, and 8 µM

5.739 µM

in-vitro,

Lung,

PC9

6.302 µM

in-vivo,

NA,

mice

"highlight2" >tumCV↓, "highlight2" >TumCP↓, "highlight2" >TumCI↓, "highlight2" >TumCMig↓, "highlight2" >Apoptosis↑, "highlight2" >PKM2↓, "highlight2" >Glycolysis↓, "highlight2" >GlucoseCon↓, "highlight2" >lactateProd↓, "highlight2" >ChemoSen↑, "highlight2" >TumVol↓, "highlight2" >TumW↓, "highlight2" >GLUT1↓,

2008-

SK,

Cisplatin,

Enhancement of cisplatin-induced colon cancer cells apoptosis by shikonin, a natural inducer of ROS in vitro and in vivo

in-vitro,

CRC,

HCT116

in-vivo,

NA,

mice

"highlight2" >ChemoSen↑, "highlight2" >selectivity↑, "highlight2" >i-ROS↑, "highlight2" >DNAdam↑, "highlight2" >MMP↓, "highlight2" >TumCCA↑, "highlight2" >eff↓, "highlight2" >*toxicity↓,

5330-

TFdiG,

Cisplatin,

Theaflavin-3,3′-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells

in-vitro,

Ovarian,

A2780S

in-vitro,

Ovarian,

OVCAR-3

"highlight2" >selectivity↑, "highlight2" >ChemoSen↑, "highlight2" >DNAdam↑, "highlight2" >GSH↓, "highlight2" >CTR1↑,

2133-

TQ,

CUR,

Cisplatin,

Thymoquinone and curcumin combination protects cisplatin-induced kidney injury, nephrotoxicity by attenuating NFκB, KIM-1 and ameliorating Nrf2/HO-1 signalling

in-vitro,

Nor,

HEK293

in-vivo,

NA,

Sprague–Dawley rats. 50 mg/kg BW Tq + 100 mg/kg BW Cur, with or without cisplatin-treatment were administered for 5 days

"highlight2" >*creat↓, "highlight2" >*TNF-α↓, "highlight2" >*IL6↓, "highlight2" >*MRP↓, "highlight2" >*GFR↑, "highlight2" >*mt-ATPase↑, "highlight2" >*p‑Akt↑, "highlight2" >*NRF2↑, "highlight2" >*HO-1↑, "highlight2" >*Casp3↓, "highlight2" >*NF-kB↓, "highlight2" >*RenoP↑,

2116-

TQ,

Cisplatin,

Oral administration of Nigella sativa oil ameliorates the effect of cisplatin on membrane enzymes, carbohydrate metabolism and oxidative damage in rat liver

in-vivo,

Nor,

rats

"highlight2" >*hepatoP↑, "highlight2" >*antiOx↑, "highlight2" >*ROS↓, "highlight2" >ALAT↓, "highlight2" >AST↓,

2099-

TQ,

Cisplatin,

Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo

in-vitro,

Lung,

H460

in-vitro,

Lung,

H146

in-vivo,

NA,

mice

"highlight2" >ChemoSen↑, "highlight2" >TumCP↓, "highlight2" >tumCV↓, "highlight2" >Apoptosis↑, "highlight2" >NF-kB↓,

4887-

ZER,

Rad,

Cisplatin,

Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma

in-vitro,

HNSCC,

CAL27

"highlight2" >Apoptosis↑, "highlight2" >ChemoSen↑, "highlight2" >RadioS↑, "highlight2" >tumCV↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 45

Pathway results for Effect on Cancer / Diseased Cells:

Infection & Microbiome ⓘ

Sepsis↓, 1,
Total Targets: 132

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

antiOx↑, 2, Ferroptosis↓, 1, HO-1↑, 3, NRF2↓, 1, NRF2↑, 2, ROS↓, 4, SOD1↑, 1,

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,

Cell Death ⓘ

p‑Akt↑, 1, Casp3↓, 1, Casp3∅, 1, Casp9∅, 1, Cyt‑c∅, 1, Ferroptosis↓, 1, iNOS↑, 1, JNK↓, 1, MAPK↓, 1,

DNA Damage & Repair ⓘ

PARP∅, 1,

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1, IGF-1↑, 1,

Migration ⓘ

mt-ATPase↑, 1,

Barriers & Transport ⓘ

MRP↓, 1,

Immune & Inflammatory Signaling ⓘ

IL6↓, 2, Inflam↓, 1, M2 MC↑, 1, NF-kB↓, 3, TNF-α↓, 2,

Clinical Biomarkers ⓘ

creat↓, 1, IL6↓, 2,

Functional Outcomes ⓘ

GFR↑, 1, hepatoP↑, 1, RenoP↑, 2, toxicity↓, 4,
Total Targets: 33

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:197  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Database Query Results : Cisplatin, ,

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Mitochondria & Bioenergetics ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Transcription & Epigenetics ⓘ

Protein Folding & ER Stress ⓘ

Autophagy & Lysosomes ⓘ

DNA Damage & Repair ⓘ

Cell Cycle & Senescence ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Barriers & Transport ⓘ

Immune & Inflammatory Signaling ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Infection & Microbiome ⓘ

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

DNA Damage & Repair ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Barriers & Transport ⓘ

Immune & Inflammatory Signaling ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Home Page